Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Theranostics 2015; 5(3):267-276. doi:10.7150/thno.10349 This issue Cite

Research Paper

Serum Fucosylated Prostate-specific Antigen (PSA) Improves the Differentiation of Aggressive from Non-aggressive Prostate Cancers

Qing Kay Li✉, Li Chen, Ming-Hui Ao, Joyce Hanching Chiu, Zhen Zhang, Hui Zhang, Daniel W Chan

Departments of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA.

✉ Corresponding author: Qing Kay Li MD. PhD. Associate Professor, Department of Pathology, The Johns Hopkins Medical Institutions, Johns Hopkins Bayview Medical Center, Baltimore, MD 21224. Phone: 410-550-0671. Fax: 410-550-0075 Email: qli23edu.

Citation:
Li QK, Chen L, Ao MH, Chiu JH, Zhang Z, Zhang H, Chan DW. Serum Fucosylated Prostate-specific Antigen (PSA) Improves the Differentiation of Aggressive from Non-aggressive Prostate Cancers. Theranostics 2015; 5(3):267-276. doi:10.7150/thno.10349. https://www.thno.org/v05p0267.htm
Other styles

File import instruction

Abstract

Background: Clinically, it is still challenging to differentiate aggressive from non-aggressive prostate cancers (Pca) by non-invasive approaches. Our recent studies showed that overexpression of alpha (1-6) fucosyltransferase played an important role in Pca cells. In this study, we have investigated levels of glycoproteins and their fucosylated glycoforms in sera of Pca patients, as well as the potential utility of fucosylated glycoproteins in the identification of aggressive Pca.

Material and Methods: Serum samples from histomorphology-proven Pca cases were included. Prostate-specific antigen (PSA), tissue inhibitor of metallopeptidase 1 (TIMP1) and tissue plasminogen activator (tPA), and their fucosylated glycoforms were captured by Aleuria Aurantia Lectin (AAL), followed by the multiplex magnetic bead-based immunoassay. The level of fucosylated glycoproteins was correlated with patients' Gleason score of the tumor.

Result: Among three fucosylated glycoproteins, the fucosylated PSA was significantly increased and correlated with the tumor Gleason score (p<0.05). The ratio of fucosylated PSA showed a marked increase in aggressive tumors in comparison to non-aggressive tumors. ROC analysis also showed an improved predictive power of fucosylated PSA in the identification of aggressive Pca.

Conclusions: Our data demonstrated that fucosylated PSA has a better predictive power to differentiate aggressive tumors from non-aggressive tumors, than that of native PSA and two other glycoproteins. The fucosylated PSA has the potential to be used as a surrogate biomarker.

Keywords: prostate cancer, multiplex immunoassay, fucosylated glycoprotein, prostate-specific antigen, TIMP1.

Citation styles

APA
Li, Q.K., Chen, L., Ao, M.H., Chiu, J.H., Zhang, Z., Zhang, H., Chan, D.W. (2015). Serum Fucosylated Prostate-specific Antigen (PSA) Improves the Differentiation of Aggressive from Non-aggressive Prostate Cancers. Theranostics, 5(3), 267-276. https://doi.org/10.7150/thno.10349.

ACS
Li, Q.K.; Chen, L.; Ao, M.H.; Chiu, J.H.; Zhang, Z.; Zhang, H.; Chan, D.W. Serum Fucosylated Prostate-specific Antigen (PSA) Improves the Differentiation of Aggressive from Non-aggressive Prostate Cancers. Theranostics 2015, 5 (3), 267-276. DOI: 10.7150/thno.10349.

NLM
Li QK, Chen L, Ao MH, Chiu JH, Zhang Z, Zhang H, Chan DW. Serum Fucosylated Prostate-specific Antigen (PSA) Improves the Differentiation of Aggressive from Non-aggressive Prostate Cancers. Theranostics 2015; 5(3):267-276. doi:10.7150/thno.10349. https://www.thno.org/v05p0267.htm

CSE
Li QK, Chen L, Ao MH, Chiu JH, Zhang Z, Zhang H, Chan DW. 2015. Serum Fucosylated Prostate-specific Antigen (PSA) Improves the Differentiation of Aggressive from Non-aggressive Prostate Cancers. Theranostics. 5(3):267-276.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use